This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Pradelli L, Iannazzo S.Pharmacoeconomic evaluation of solifenacin in the treatment of overactive bladder syndrome in Italy. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 650-651 abstr. PUK4, 8 Nov 2008
Cardozo L, Thorpe A, Grishchenko M, Sidhu MK.A cost-utility analysis of solifenacin 5 mg and solifenacin 10 mg versus tolterodine ER 4 mg in the pharmacological treatment of patients with overactive bladder. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 653 abstr. PUK11, 8 Nov 2008
Cardozo L, Thorpe A, Grishchenko M, Sidhu MK.A cost-utility analysis of solifenacin 5 mg and 10 mg versus fesoterodine 4 mg and 8 mg in the pharmacological tratment of patients with overactive bladder in the UK NHS. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 653 abstr. PUK12, 8 Nov 2008
Kelleher C, Snedecor SJ, Botteman MF, Lee R, Najib H, Weinstein D, Trocio JN.Fesoterodine is cost-effective for the treatment of overactive bladder: results of an economic model. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: 652 abstr. PUK8, 8 Nov 2008
Rights and permissions
About this article
Cite this article
Overactive bladder treatments prove their worth. Pharmacoecon. Outcomes News 567, 7 (2008). https://doi.org/10.2165/00151234-200805670-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805670-00007